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Introduction
Prostate cancer (PCa) and prostate specific antigen
(PSA) screening have been the main focus of discussions
among urologists and primary care physicians during the last
few years 
1. Ever since its introduction in the 1980s 
2–4, PSA
screening was implemented as standard of care in many de-
veloped countries, but without the supporting level I evi-
dence to justify its initiation (mainly relating to reduction in
cancer-specific mortality). Several retrospective reports, such
as the Surveillance, Epidemiology, and End Results (SEER)
database review suggested a significant decline in mortality
rates of 32.5% from PCa due to screening; the Baltimore
Longitudinal Study of Aging (BLSA) showed that PSA lev-
els increased years before clinically detectable PCa and that
this could lead to an effective early diagnosis and more ef-
fective therapy 
5. Similar findings were observed in the study
from Tyrol, Austria, where men from this particular region
had a notable decrease in mortality after being screened with
PSA in comparison to the rest of the country where PSA
testing was not freely available 
6. However, in 2009 two
large, randomized, prospective studies attempted to answer
this decade-long question: The Prostate, Lung, Colorectal
and Ovarian Cancer screening trial (PLCO) from the United
States which showed no benefit to screening 
7, 8, and the
European Randomized Trial of Screening for Prostate Can-
cer (ERSPC) which reported a 20% reduction in mortality
from PCa, but at the expense of 1,410 men having to un-
dergo screening and additional 48 men to undergo treatment
in order to save 1 life 
9–11. The latter results implied a signifi-
cant overtreatment and overdiagnosis of clinically insignifi-
cant cancers as a result of screening. Although survival rates
after radical management of localized PCa are high, the risk
of complications including urinary, sexual, and bowel dys-
function is not negligible 
12, 13.
Based on these findings, the United States Preventive
Services Task Force (USPSTF) after careful review and bal-
ance of the risks and benefits – mainly, problems of overdi-
agnosis and over-treatment – recommended against a popu-
lation-based screening program 
14. The rationale for screen-
ing after inconsistent results from these two large, random-
ized trials coupled with the inherent PCa treatment compli-
cations (including urinary, sexual, and bowel dysfunction)
created a conflicting and confusing environment for the
world-wide treating physicians and their patients. While
many questions still remain unanswered, PSA (although an
imperfect test) continues to be the only tool we currently
have available to identify patients at higher risk of dying
from PCa.
Adaption of new risk stratification strategies may be the
solution to minimize patient harms and offset the risk/benefit
ratio. In this report we provide evidence in support of early
and targeted screening, earlier termination of screening, and
prolongation of the screening interval to every 2–4 years.
Early “targeted” screening
Based on the observational data from Sweden 
15, PSA
screening when performed earlier in patient’s life seems to
provide strong prognostic risks relating to future develop-
ment of clinically important PCa. Lilja et al. 
15 reported that a
single PSA test obtained in the middle-aged men (ages 45–
50) had a highly predictive risk of developing subsequent
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ng/mL had a cumulative low (10.5%) risk of developing
clinically meaningful cancer by age of 75, those with PSA
between 0.51 ng/mL and 1.0 ng/mL had a 2.5-fold increased
risk, and men with PSA between 2.0–3.0 ng/mL were associ-
ated with a 19-fold increased risk of developing cancer 
15.
Similarly, Vickers et al. 
16 reported that men with PSA  1.0
ng/mL at age 60 were highly unlikely to possess or develop
life threatening PCa by age 85, and even lower risk (0.2%) of
dying from disease.
These data are further supported by the findings ob-
served by Stamey et al.
 17 regarding correlation between PSA
level at radical prostatectomy and final pathology. After a
careful evaluation of almost 1,300 specimens, they docu-
mented a strong association between the increasing PSA lev-
els and prostate weight, or benign prostate hyperplasia
(BPH), but not PCa 
17. These observations imply that as men
age and their prostates increase in size (mostly due to BPH),
the PSA tends to loose its specificity for diagnosing PCa. As
a result, in the current PSA era the main “driver” for PSA
rise in older men seems to be mostly related to the amount of
BPH. Therefore, “targeted” screening with focus on younger
population where BPH represents a minimal confounder
should improve the usefulness of PSA testing.
Based on these findings, early PSA elevation could
identify a cohort of men who would benefit from early
screening and/or preventive measures (pharmacological or
lifestyle alterations) 
18. Similarly, in those men without early
PSA elevation screening could be potentially deferred until
age 50 and obtained less frequently 
19. In cases with early
PSA elevation, patients should only undergo biopsy if recog-
nized indications for biopsy are present, such as PSA > 1.0
ng/mL, PSA velocity (v) > 0.75 ng/mL/year, free: total PSA
< 10%, and those with strong family history of early PCa.
Early “termination” of screening
There is strong evidence from previous reports that
screening men for PCa in the PSA era should be stopped
earlier than current guidelines would suggest. According to
a population-based study from the pre-PSA era by Albert-
sen et al. 
20, a significant number of PCa identified today
(in the PSA era) would unlikely become clinically symp-
tomatic over a patient’s lifetime. This was especially true
for well-differentiated tumors (Gleason 5–6), in which case
the majority of men died from the competing medical con-
ditions during a 15–20 years follow-up 
20. Interestingly,
Draisma et al. 
21 estimated the impact of PSA testing on
lead-time of detecting clinically insignificant disease to be
12 years for 55-year-old men, and estimated that approxi-
mately half of the men ages 55–67 diagnosed with PCa
would have non-important disease. This suggests that
screening should probably be stopped for healthy men with
a low-risk of developing PCa around age 60–65, given the
long lead-time and natural history of disease. As mentioned
earlier, Vickers et al. 
16 demonstrated in their study the risk
of PCa death for men with PSA < 1.0 ng/mL at age 60 to be
negligible. Therefore, termination of screening at later age
(like 75) as American Urology Association (AUA) guide-
lines recommend should be considered only in highly select
cases – those who are healthy and have a life expectancy of
> 10–15 years.
Risk stratification for prolonged screening interval
The ERSPC 
10 study, which clearly showed a reduction
in PCa-specific mortality due to screening, was based on a
2–4 year PSA screening interval. However, further subanaly-
ses of the study seemed to support a potential for even fur-
ther risk stratification and prolongation of screening time in-
terval. For example, Roobol et al. 
22 evaluated a group of
men with initially low PSA (< 1ng/mL) who underwent
every 4–8 years screening interval and found only 0.23% risk
of cancer diagnosis during the intervening visit. Another
study showed a 0.5% risk of advanced disease and overall
2.5% risk of prostate cancer at 15 years follow-up 
23. On the
other hand, van Leeuwen et al. 
24 compared men from Goth-
enburg screening cohort (2-year screening interval) to Rot-
terdam cohort (4-year screening interval) and found that
more frequent screening resulted in a higher proportion of
screen-detected cancers (RR:1.18, p = 0.009). However,
more frequent screening also led to increased incidence of
clinically insignificant (low-risk) PCa (RR: 1.46, p < 0.001).
Interestingly, the Gothenburg cohort also had a lower inci-
dence of advanced cancer during the last follow-up (RR:
0.57, p = 0.048), which implied that more frequent screening
resulted into more effective way of eliminating high-risk PCa
from the population. Importantly, the effect on PCa-related
mortality remained uncertain. This study implies that there is
a certain population of men that may benefit from a more
frequent screening program, but an individualized approach
according to patient risks would be the most optimal way of
screening. Currently, there is no data that supports annual
PSA screening for PCa – the best evidence is based on
screening every 4 years 
10.
Conclusion
According to recent studies, PSA results obtained dur-
ing an earlier age may be strongly predictive of long-term
risk of clinically important PCa, and as a result a risk-
stratification approach should be considered in order to
minimize over-diagnosis and overtreatment of this disease.
The focus of screening should become on tumors with
greater malignant potential in the appropriate age population,
instead of clinically insignificant tumors. Such an approach
could also reduce associated economic burden of treating
PCa in the present health-care system. Until new genomic-
based markers are identified, PSA testing will continue to
play an important role in identifying patients with high-risk
PCa and should not be abandoned.Volumen 70, Broj 5 VOJNOSANITETSKI PREGLED Strana 503
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